EUVIMEDScopri EUVIMED
Crossref

Standards for palliative systemic therapy in Germany – A survey of the DGHNO Oncology Working Group

Michael Sonntag, Jule M. Heil, Thomas Hoffmann, Shachi Jenny Sharma, Sami Shabli, Henrike Zech, Christian Betz, Susanne Wiegand, Andreas Dietz, Roman Braun, Gregor Wolf, Sabine Eichhorn and 21 more

Laryngo-Rhino-Otologie · 2024-05-01 · 103 (S 02 S 02) · S202-S203

DOI: 10.1055/s-0044-1784653 ↗

At a glance

Journal article in Laryngo-Rhino-Otologie, published on 2024-05-01. Written by Michael Sonntag and 32 co-authors.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Medical tumor therapy (MTT) of head and neck tumors (HNT) is gaining increasing importance. Since the last survey on medical tumor therapy (2013/14), new drugs have been approved for palliative systemic therapy of HNT. There is room for interpretation in the selection of systemic therapy. This survey aims to provide an overview of standards in MTT for head and neck tumors.

Methods

From 10/22 to 07/23, an online survey (Limesurvey) was conducted by the Oncology Working Group of the German Society for Otorhinolaryngology, Head and Neck Surgery (DGHNO), targeting all 172 ENT clinics in Germany.

Results

51 out of 172 clinics participated in the survey. Palliative systemic therapy is offered in 49 of these clinics. The therapy is conducted by 19 ENT clinics, 5 maxillofacial surgery departments, 38 oncology clinics, and 26 oncology practices (multiple responses possible). The analysis of PD-L1 expression in the tumor was considered a standard by 37 participants. Only 8 out of 51 clinics use the Companion Diagnostic antibody for Pembrolizumab (22C3), while the majority use other diagnostic PD-L1 antibodies. For CPS =20, the preference is reversed (Pembro Mono: 33/51; Pembro+Chemo: 8/51). The significance of other influencing factors (tumor burden, progression pressure, general condition, PD-L1, platinum pretreatment) is evaluated differently depending on the CPS group.

Conclusion

Different antibodies are used to determine the PD-L1 status. There is a high level of homogeneity in the interpretation of standards in first-line therapy. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Cite

APA

Sonntag, M., Heil, J. M., Hoffmann, T., Sharma, S. J., Shabli, S., Zech, H., Betz, C., Wiegand, S., Dietz, A., Braun, R., Wolf, G., Eichhorn, S., Park, J., Evers, T., Tisch, M., Federspil, P. A., Heidemann, J., Hofmann, V. M., Herzog, M., …, & Laban, S. (2024). Standards for palliative systemic therapy in Germany – A survey of the DGHNO Oncology Working Group. Laryngo-Rhino-Otologie, 103(S 02 S 02), S202-S203. https://doi.org/10.1055/s-0044-1784653

Vancouver

Sonntag M, Heil JM, Hoffmann T, Sharma SJ, Shabli S, Zech H, et al. Standards for palliative systemic therapy in Germany – A survey of the DGHNO Oncology Working Group. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S202-S203. doi:10.1055/s-0044-1784653

BibTeX
@article{Sonntag2024,
  author = {Sonntag, Michael and Heil, Jule M. and Hoffmann, Thomas and Sharma, Shachi Jenny and Shabli, Sami and Zech, Henrike and Betz, Christian and Wiegand, Susanne and Dietz, Andreas and Braun, Roman and Wolf, Gregor and Eichhorn, Sabine and Park, Jonas and Evers, Theo and Tisch, Matthias and Federspil, Philippe A. and Heidemann, Jan and Hofmann, Veit M. and Herzog, Michael and Kisser, Ulrich and Abbaspour, Bektasch and Thomas, Jan Peter and Kürten, Cornelius and Lang, Stephan and Warnecke, Athanasia and Lenarz, Thomas and Schapher, Mirco and Traxdorf, Maximilian and Döscher, Johannes and Wirth, Markus and Wollenberg, Barbara and Klußmann, Jens Peter and Laban, Simon},
  title = {Standards for palliative systemic therapy in Germany – A survey of the DGHNO Oncology Working Group},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S202--S203},
  doi = {10.1055/s-0044-1784653}
}
Start for free →